Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  American Journal of Hypertension

• Publication date

  2004-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.AMJHYPER.2003.09.014PMID 14751650
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Physician-related barriers to the effective management of uncontrolled hypertension.

  2002cited by this paper
• Original Papers. Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

  2002cited by this paper
• Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)

  2002cited by this paper
• Goal-Oriented Hypertension Management: Translating Clinical Trials to Practice

  2002cited by this paper
• Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial

  2001cited by this paper
• Omapatrilat Versus Lisinopril: Efficacy and Neurohormonal Profile in Salt-Sensitive Hypertensive Patients

  2001cited by this paper
• P-607: The effect of increasing age on hypertension control rates

  2001cited by this paper
• A085: Omapatrilat compared with lisinopril in treatment of hypertension as assessed by ambulatory blood pressure monitoring

  2000cited by this paper
• OMAPATRILAT COMPARED WITH LISINOPRIL IN TREATMENT OF HYPERTENSION AS ASSESSED BY AMBULATORY BLOOD PRESSURE MONITORING: P2.25

  2000cited by this paper
• Blood pressure control in a hypertension hospital clinic.

  1999cited by this paper
• Inadequate management of blood pressure in a hypertensive population.

  1999cited by this paper
• Antihypertensive efficacy of Omapatrilat, a vasopeptidase inhibitor, compared with lisinopril.

  1999cited by this paper
• The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)

  1998cited by this paper
• Inadequate management of blood pressure in a hypertensive population.

  1998cited by this paper
• Blood pressure as a cardiovascular risk factor: prevention and treatment.

  1996cited by this paper
• Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991.

  1995cited by this paper

• High‐Throughput Screening for Prescribing Cascades Among Real‐World Angiotensin‐II Receptor Blockers (ARBs) Initiators

  2025cites this paper
• Novel pharmacological approaches to lowering blood pressure and managing hypertension

  2025cites this paper
• High-Throughput Screening for Prescribing Cascades Among Real-World Angiotensin-II Receptor Blockers (ARBs) Initiators

  2025cites this paper
• Pharmacological Countermeasures for Long-Duration Space Missions: Addressing Cardiovascular Challenges and Advancing Space-Adapted Healthcare.

  2025cites this paper
• Research progress and perspectives of dual-target inhibitors.

  2025cites this paper
• Advances in Cardiovascular Pharmacotherapy. VI. Sacubitril-Valsartan, An Angiotensin Receptor-Neprilysin Inhibitor.

  2025cites this paper
• Potential renoprotective effects and possible underlying mechanisms of angiotensin receptor-neprilysin inhibitors in cardiorenal syndrome

  2025cites this paper
• Risk factors for angiotensin converting enzyme inhibitor angioedema in a South African population

  2025cites this paper
• High‐Throughput Screening for Prescribing Cascades Among Real‐World Angiotensin‐Converting Enzyme Inhibitor Initiators

  2025cites this paper
• Design of Novel Mercapto-3-phenylpropanoyl Dipeptides as Dual Angiotensin-Converting Enzyme C–Domain-Selective/Neprilysin Inhibitors

  2025cites this paper
• Multi-Target In-Silico modeling strategies to discover novel angiotensin converting enzyme and neprilysin dual inhibitors

  2024cites this paper
• The renin-angiotensin-aldosterone system: An old tree sprouts new shoots.

  2024cites this paper
• Substance Use Disorder as Risk Factor for Intubation in Angioedema: A Nationwide Cohort Study

  2024cites this paper
• Research Progress of Sacubitril/Valsartan in the Treatment of Patients with Resistant Hypertension

  2024cites this paper
• Angiotensin Receptor Blocker-Neprilysin Inhibitor for Heart Failure with Reduced Ejection Fraction.

  2024cites this paper
• Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure Patients With Renal Dysfunction

  2024cites this paper
• New therapeutic targets in hypertension.

  2024cites this paper
• Comprehensive review on neprilysin (NEP) inhibitors: design, structure-activity relationships, and clinical applications

  2024cites this paper
• Angiœdème bradykinique héréditaire : à propos d’un cas homozygote décrit au Niger et revue de la littérature

  2024cites this paper
• Inhibition de la néprilysine dans le traitement de l’insuffisance cardiaque

  2024cites this paper
• Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone

  2024cites this paper
• Efficacy and safety of angiotensin receptor–neprilysin inhibition in heart failure patients with end‐stage kidney disease on maintenance dialysis: A systematic review and meta‐analysis

  2024cites this paper
• Neprilysin Inhibitors: History, Pharmacology, Pharmacological-Clinical Evidence, and Clinical Practice, from the Risk of Angioedema to a Pillar of Therapy in Heart Failure

  2024cites this paper
• LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Ameliorates Endothelial Dysfunction in Diabetic C57BL/6 Mice

  2024cites this paper
• Contact System Activation and Bradykinin Generation in Angioedema: Laboratory Assessment and Biomarker Utilization.

  2024cites this paper
• Guidelines for Treating Heart Failure.

  2024cites this paper
• New therapeutic targets in hypertension

  2024cites this paper
• Inibidores da Neprilisina: Histórico, Farmacologia, Evidência Farmacológico-clínica e Prática Clínica, do Risco de Angioedema ao Pilar Terapêutico na Insuficiência Cardíaca

  2024cites this paper
• The bradykinin-forming cascade in anaphylaxis and ACE-inhibitor induced angioedema/airway obstruction

  2024cites this paper
• Cross talk on therapeutic strategies: natriuretic peptides and inhibiting neprilysin in hypertension management

  2024cites this paper
• A perspective on the development of small molecular neprilysin inhibitors (NEPi) with emphasis on cardiorenal disease.

  2024cites this paper
• Updates for Cardio‐Kidney Protective Effects by Angiotensin Receptor‐Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection

  2023cites this paper
• The real-world safety of sacubitril / valsartan among older adults (≥75): A pharmacovigilance study from the FDA data.

  2023cites this paper
• Over diagnosis of bradykinin angioedema in patients treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers

  2023cites this paper
• Bradykinin-Mediated Angioedema Induced by Commonly Used Cardiovascular Drugs

  2023cites this paper
• The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure

  2023cites this paper
• Signaling Pathways and Potential Therapeutic Strategies in Cardiac Fibrosis

  2023cites this paper
• Heart failure with reduced ejection fraction: What’s new in the 2022 guideline?

  2023cites this paper
• Autoregulation: mediators and renin–angiotensin system in diseases and treatments

  2023cites this paper
• Sacubitril/Valsartan in Dialysis Patients: Update on Current Perspectives

  2023cites this paper
• Sacubitril/valsartan in peritoneal dialysis - lessons from a pharmacokinetic study.

  2023cites this paper
• We Need Subject Matter Expertise to Choose and Identify Causal Estimands: Comment on “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event”

  2023cites this paper
• Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors.

  2023cites this paper
• The Real-World Price of Switching to an ARNI: A Case for De Novo Sacubitril/Valsartan Initiation.

  2023cites this paper
• 1821–2021: Contributions of physicians and researchers of Greek descent in the advancement of clinical and experimental cardiology and cardiac surgery

  2023cites this paper
• Transient Receptor Potential Channels, Natriuretic Peptides, and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure

  2022cites this paper
• Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study.

  2022cites this paper
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2022cites this paper
• Combining Neprilysin Inhibitor With AT2R Agonist Is Superior to Combination With AT1R Blocker in Providing Reno-Protection in Obese Rats

  2022cites this paper
• Renal events in patients receiving Neprilysin inhibitors: a systematic review and meta-analysis.

  2022cites this paper
• The Design of Multi-target Drugs to Treat Cardiovascular Diseases: Two (or more) Birds on one Stone.

  2022cites this paper
• Probing the Requirements for Dual Angiotensin-Converting Enzyme C-Domain Selective/Neprilysin Inhibition.

  2022cites this paper
• Unrecognized recurrent perioperative angioedema requiring intubation in a patient taking long-term angiotensin-converting enzyme inhibitor therapy

  2022cites this paper
• Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995–2021

  2022cites this paper
• Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs—Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers

  2022cites this paper
• Potential role of angiotensin converting enzyme/neprilysin pathway and protective effects of omapatrilat for paracetamol‑induced acute liver injury.

  2022cites this paper
• Angiotensin Receptor Neprilysin Inhibitor Use and Blood Pressure Lowering in Patients With Heart Failure With Reduced Ejection Fraction Across the Spectrum of Kidney Function: An Analysis of the Veterans Administrative Health System.

  2022cites this paper
• Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction.

  2022cites this paper
• Varón de 57 años con edema penoescrotal

  2022cites this paper
• Heart Failure

  2022cites this paper
• Efficacy of human C1 esterase inhibitor concentrate for treatment of ACE-inhibitor induced angioedema.

  2022cites this paper
• Molecular Mechanism of Blood Pressure Regulation through the Atrial Natriuretic Peptide

  2022cites this paper
• Novel antihypertensive agents for resistant hypertension: what does the future hold?

  2022cites this paper
• Neprilysin Inhibitors in Heart Failure

  2022cites this paper
• Real-World Usage of Sacubitril/Valsartan in Korea: A Multi-Center, Retrospective Study

  2022cites this paper
• Natriuretic peptides: new challenges — new solutions

  2021cites this paper
• The Natriuretic Peptides for Hypertension Treatment

  2021cites this paper
• Incidence and Risk Factors of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema: A Large Case-Control Study.

  2021cites this paper
• Association of Variants Near the Bradykinin Receptor B2 Gene With Angioedema in Patients Taking ACE Inhibitors.

  2021cites this paper
• Angiotensin-converting enzyme inhibitor induced angioedema: not always a class effect? A case report and short narrative review

  2021cites this paper
• Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined With Inhibition of NEP (Neprilysin)

  2021cites this paper
• Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment

  2021cites this paper
• Current concept in the diagnosis, treatment and rehabilitation of patients with congestive heart failure

  2021cites this paper
• Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats

  2021cites this paper
• The Road to Better Management in Resistant Hypertension—Diagnostic and Therapeutic Insights

  2021cites this paper
• Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology

  2021cites this paper
• Sacubitril/valsartan in chronic kidney disease: From pharmacological mechanism to clinical application.

  2021cites this paper
• Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias

  2021cites this paper
• Hypertension: Current trends and future perspectives

  2021cites this paper
• Effectiveness of C1-INH therapy in angiotensin converting enzyme inhibitor induced angioedema

  2021cites this paper
• Renal protective effect of sacubitril/valsartan in patients with heart failure

  2021cites this paper
• Critical angioedema induced by a renin angiotensin system blocker in the contemporary era of increasing heart failure: A case report and commentary

  2021cites this paper
• Myocardial protective effect of sacubitril-valsartan on rats with acute myocardial infarction

  2021cites this paper
• Efficacy and Safety of LCZ696 for Short-term Management of Essential Hypertension Compared With ARBs: A Meta-analysis of Randomized Controlled Trials

  2021cites this paper
• Toward a New Paradigm for Targeted Natriuretic Peptide Enhancement in Heart Failure

  2021cites this paper
• Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening!

  2021cites this paper
• Mechanisms and Models in Heart Failure: A Translational Approach.

  2021cites this paper
• Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?

  2020cites this paper
• TCRM_A_234772 715..726

  2020cites this paper
• Updates in pharmacotherapy of heart failure with reduced ejection fraction

  2020cites this paper
• Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF.

  2020cites this paper
• Sacubitril/Valsartan in the Management of Heart Failure Patients with Cardiac Implantable Electronic Devices

  2020cites this paper
• Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date.

  2020cites this paper
• Effects of Angiotensin-Neprilysin Inhibition in Canines with Experimentally-Induced Cardiorenal Syndrome.

  2020cites this paper
• Angioedema, ACE inhibitor and COVID-19

  2020cites this paper
• Management of patients with heart failure: focus on new pharmaceutical and device options.

  2020cites this paper
• Effects of sacubitril/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction

  2020cites this paper
• Natriuretic peptides and neprilysin inhibition in hypertension and hypertensive organ damage.

  2020cites this paper
• New and emerging cardiovascular and antihypertensive drugs

  2020influential citation
• Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!

  2020cites this paper